Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

Author： Awada A.   Eskens F.A.L.M.   Piccart M.   Cutler D.L.   van der Gaast A.   Bleiberg H.   Wanders J.   Faber M.N.   Statkevich P.   Fumoleau P.   Verweij J.   for the EORTC Early Clinical Studies Group  

Publisher： Elsevier

ISSN： 0959-8049

Source： European Journal of Cancer, Vol.38, Iss.17, 2002-11, pp. : 2272-2278

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

By Crul M.   Rosing H.   de Klerk G.J.   Dubbelman R.   Traiser M.   Reichert S.   Knebel N.G.   Schellens J.H.M.   Beijnen J.H.   ten Bokkel Huinink W.W.  

European Journal of Cancer, Vol. 38, Iss. 12, 2002-08 ,pp. : 1615-1621

Elsevier

Access to resources Recommend Favorite

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

By Wong Nan Soon   Meadows Kellen L.   Rosen Lee S.   Adjei Alex A.   Kaufmann Scott H.   Morse Michael A.   Petros William P.   Zhu Yali   Statkevich Paul   Cutler David L.   Meyers Michael L.   Hurwitz Herbert I.  

Cancer Investigation, Vol. 29, Iss. 9, 2011-10 ,pp. : 617-625

Informa Healthcare

Access to resources Recommend Favorite

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

By Chow Laura   Eckhardt S.   O’Bryant Cindy   Schultz Mary   Morrow Mark   Grolnic Stacy   Basche Michele   Gore Lia  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 631-646

Springer Publishing Company

Access to resources Recommend Favorite

Five days of oral topotecan (hycamtin ( R)), a phase I and pharmacological study in adult patients with solid tumours

By Gerrits C.J.H.   Burris H.   Schellens J.H.M.   Planting A.S.T.   van den Burg M.E.L.   Rodriguez G.I.   van Beurden V.   Loos W.J.   Hudson I.   Fields S.   Verweij J.   von Hoff D.D.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 1030-1035

Elsevier

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer

By Cohen Steven   Gallo James   Lewis Nancy   Alpaugh R.   Gentner Louis   Rogatko André   Yeslow Gwen   Schol Jessie   Verhaeghe Tom   Zannikos Peter   Palmer Peter   Weiner Louis   Meropol Neal  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 6, 2004-06 ,pp. : 513-518

Springer Publishing Company

Access to resources Recommend Favorite